WO2004075840A2 - Selective non-steroidal glucocorticoid receptor modulators - Google Patents
Selective non-steroidal glucocorticoid receptor modulators Download PDFInfo
- Publication number
- WO2004075840A2 WO2004075840A2 PCT/US2004/005199 US2004005199W WO2004075840A2 WO 2004075840 A2 WO2004075840 A2 WO 2004075840A2 US 2004005199 W US2004005199 W US 2004005199W WO 2004075840 A2 WO2004075840 A2 WO 2004075840A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- independently selected
- items
- optionally substituted
- halo
- Prior art date
Links
- 0 C[C@@](C1)([C@@](CC2)N(C)*)C2=Cc2c1cn[n]2-c(cc1)ccc1F Chemical compound C[C@@](C1)([C@@](CC2)N(C)*)C2=Cc2c1cn[n]2-c(cc1)ccc1F 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
Abstract
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/544,899 US7411073B2 (en) | 2003-02-25 | 2004-02-20 | Selective non-steroidal glucocorticoid receptor modulators |
JP2006503780A JP4648303B2 (en) | 2003-02-25 | 2004-02-20 | Selective non-steroidal glucocorticoid receptor modulators |
AT04713398T ATE464296T1 (en) | 2003-02-25 | 2004-02-20 | SELECTIVE NONSTEROID GLUCOCORTICOID RECEPTOR MODULATORS |
EP04713398A EP1599201B1 (en) | 2003-02-25 | 2004-02-20 | Selective non-steroidal glucocorticoid receptor modulators |
AU2004216182A AU2004216182B2 (en) | 2003-02-25 | 2004-02-20 | Selective non-steroidal glucocorticoid receptor modulators |
DE602004026558T DE602004026558D1 (en) | 2003-02-25 | 2004-02-20 | SELECTIVE NON-TTEROIDAL GLUCOCORTICOID RECEPTOR MODULATORS |
CA002516684A CA2516684A1 (en) | 2003-02-25 | 2004-02-20 | Selective non-steroidal glucocorticoid receptor modulators |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45081103P | 2003-02-25 | 2003-02-25 | |
US60/450,811 | 2003-02-25 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2004075840A2 true WO2004075840A2 (en) | 2004-09-10 |
WO2004075840A3 WO2004075840A3 (en) | 2005-02-03 |
WO2004075840A9 WO2004075840A9 (en) | 2005-08-04 |
Family
ID=32927681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/005199 WO2004075840A2 (en) | 2003-02-25 | 2004-02-20 | Selective non-steroidal glucocorticoid receptor modulators |
Country Status (8)
Country | Link |
---|---|
US (1) | US7411073B2 (en) |
EP (1) | EP1599201B1 (en) |
JP (1) | JP4648303B2 (en) |
AT (1) | ATE464296T1 (en) |
AU (1) | AU2004216182B2 (en) |
CA (1) | CA2516684A1 (en) |
DE (1) | DE602004026558D1 (en) |
WO (1) | WO2004075840A2 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1617806A2 (en) * | 2003-04-23 | 2006-01-25 | Merck & Co., Inc. | Selective spirocyclic glucocorticoid receptor modulators |
WO2006138373A2 (en) | 2005-06-14 | 2006-12-28 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF |
WO2008051532A1 (en) * | 2006-10-23 | 2008-05-02 | Merck & Co., Inc. | 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydroclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands |
EP1916896A2 (en) * | 2005-08-26 | 2008-05-07 | The Regents of The University of California | Non-steroidal antiandrogens |
WO2009054925A1 (en) * | 2007-10-23 | 2009-04-30 | Merck & Co., Inc. | Process for making glucocorticoid receptor ligands |
EP2268630A2 (en) * | 2008-02-26 | 2011-01-05 | Merck Sharp & Dohme Corp. | Hexahydrocyclopentylýf¨indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators |
EP2482659A1 (en) * | 2009-09-08 | 2012-08-08 | Schering Corporation | HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
EP2493302A1 (en) * | 2009-10-30 | 2012-09-05 | Merck Sharp & Dohme Corp. | Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators |
EP2493303A1 (en) * | 2009-10-30 | 2012-09-05 | Merck Sharp & Dohme Corp. | 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS |
WO2018191283A1 (en) * | 2017-04-11 | 2018-10-18 | Oric Pharmaceuticals, Inc. | Glucocorticoid receptor modulators |
WO2020076999A1 (en) * | 2018-10-10 | 2020-04-16 | Oric Pharmaceuticals, Inc. | Glucocorticoid receptor modulators |
WO2020152193A1 (en) | 2019-01-22 | 2020-07-30 | Akribes Biomedical Gmbh | Selective glucocorticoid receptor modifiers for treating impaired skin wound healing |
CN112771046A (en) * | 2018-07-20 | 2021-05-07 | 格吕伦塔尔有限公司 | Other substituted triazoloquinoxaline derivatives |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6831093B2 (en) * | 2002-01-22 | 2004-12-14 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
DE60335869D1 (en) * | 2002-04-11 | 2011-03-10 | Merck Sharp & Dohme | 1H-BENZO (F) INDAZOL-5-YL DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
TW201422590A (en) | 2012-09-07 | 2014-06-16 | Abbvie Inc | Heterocyclic nuclear hormone receptor modulators |
EP2935284A4 (en) | 2012-12-21 | 2016-04-27 | Abbvie Inc | Heterocyclic nuclear hormone receptor modulators |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4349559A (en) | 1981-02-19 | 1982-09-14 | Sterling Drug Inc. | Anti-inflammatory spiro-2H-indene-[2,3']-3H-pyrazolo[4",5":7',6']naphtho[2,1-b]pyran-1,3-dione derivatives |
WO2003086294A2 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3932388A (en) * | 1974-04-22 | 1976-01-13 | Schering Corporation | -Azido-4,6-pregnadieno(3,2-c)pyrazoles, processes for their preparation and intermediates useful therein |
US4349558A (en) | 1981-02-19 | 1982-09-14 | Sterling Drug Inc. | Anti-inflammatory 8H-phenanthro-[2,3-c]pyrazole derivatives |
EP0058841B1 (en) | 1981-02-19 | 1984-12-12 | Sterling Drug Inc. | Phenylpyrazole compounds useful as anti-inflammatory agents and preparation thereof |
US4307102A (en) | 1981-02-19 | 1981-12-22 | Sterling Drug Inc. | Phenanthro[2,3-c]pyrazole |
US6831093B2 (en) * | 2002-01-22 | 2004-12-14 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
WO2004026248A2 (en) | 2002-09-20 | 2004-04-01 | Merck & Co., Inc. | Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators |
-
2004
- 2004-02-20 US US10/544,899 patent/US7411073B2/en not_active Expired - Fee Related
- 2004-02-20 AU AU2004216182A patent/AU2004216182B2/en not_active Ceased
- 2004-02-20 WO PCT/US2004/005199 patent/WO2004075840A2/en active Application Filing
- 2004-02-20 JP JP2006503780A patent/JP4648303B2/en not_active Expired - Fee Related
- 2004-02-20 CA CA002516684A patent/CA2516684A1/en not_active Abandoned
- 2004-02-20 AT AT04713398T patent/ATE464296T1/en not_active IP Right Cessation
- 2004-02-20 DE DE602004026558T patent/DE602004026558D1/en not_active Expired - Lifetime
- 2004-02-20 EP EP04713398A patent/EP1599201B1/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4349559A (en) | 1981-02-19 | 1982-09-14 | Sterling Drug Inc. | Anti-inflammatory spiro-2H-indene-[2,3']-3H-pyrazolo[4",5":7',6']naphtho[2,1-b]pyran-1,3-dione derivatives |
WO2003086294A2 (en) | 2002-04-11 | 2003-10-23 | Merck & Co., Inc. | 1h-benzo[f]indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
Non-Patent Citations (2)
Title |
---|
"Recent Advances in Glucocorticoid Receptor Action", 2002, SPRINGER-VERLAG: BERLIN-HEIDELBERG |
COGHLAN, M.J. ET AL.: "Annual Reports in Medicinal Chemistry", vol. 37, 2002, ACADEMIC PRESS, pages: 167 - 176 |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1617806A4 (en) * | 2003-04-23 | 2006-11-02 | Merck & Co Inc | Selective spirocyclic glucocorticoid receptor modulators |
EP1617806A2 (en) * | 2003-04-23 | 2006-01-25 | Merck & Co., Inc. | Selective spirocyclic glucocorticoid receptor modulators |
US7662846B2 (en) | 2003-04-23 | 2010-02-16 | Merck Sharp & Dohme Corp. | Selective spirocyclic glucocorticoid receptor modulators |
WO2006138373A2 (en) | 2005-06-14 | 2006-12-28 | Bristol-Myers Squibb Company | MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF |
US7888381B2 (en) | 2005-06-14 | 2011-02-15 | Bristol-Myers Squibb Company | Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof |
US7645885B2 (en) | 2005-08-26 | 2010-01-12 | The Regents Of The University Of California | Non-steroidal antiandrogens |
EP1916896A2 (en) * | 2005-08-26 | 2008-05-07 | The Regents of The University of California | Non-steroidal antiandrogens |
EP1916896A4 (en) * | 2005-08-26 | 2010-08-11 | Univ California | Non-steroidal antiandrogens |
JP2009506077A (en) * | 2005-08-26 | 2009-02-12 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Non-steroidal antiandrogen |
WO2008051532A1 (en) * | 2006-10-23 | 2008-05-02 | Merck & Co., Inc. | 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydroclopenta[f]indazol-5-yl]ethyl phenyl derivatives as glucocorticoid receptor ligands |
WO2008060391A3 (en) * | 2006-10-23 | 2008-09-25 | Merck & Co Inc | 2- [l-phenyl-5-hydr0xy-4alpha-methyl-hexahydr0cycl0penta[f] indaz0l-5-yl] ethyl phenyl derivatives as glucocorticoid receptor ligands |
US8119681B2 (en) | 2006-10-23 | 2012-02-21 | Merck Sharp & Dohme Corp. | 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta [ƒ]indazole-5-YL]ethyl phenyl derivatives as glucocorticoid receptor ligands |
WO2008060391A2 (en) * | 2006-10-23 | 2008-05-22 | Merck & Co., Inc. | 2- [l-phenyl-5-hydr0xy-4alpha-methyl-hexahydr0cycl0penta[f] indaz0l-5-yl] ethyl phenyl derivatives as glucocorticoid receptor ligands |
WO2009054925A1 (en) * | 2007-10-23 | 2009-04-30 | Merck & Co., Inc. | Process for making glucocorticoid receptor ligands |
EP2268630A4 (en) * | 2008-02-26 | 2011-03-09 | Merck Sharp & Dohme | Hexahydrocyclopentylýf¨indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators |
US8338472B2 (en) | 2008-02-26 | 2012-12-25 | Merck Sharp & Dohme Corp. | Hexahydrocyclopentyl[F]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators |
EP2268630A2 (en) * | 2008-02-26 | 2011-01-05 | Merck Sharp & Dohme Corp. | Hexahydrocyclopentylýf¨indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators |
EP2482659A1 (en) * | 2009-09-08 | 2012-08-08 | Schering Corporation | HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
EP2482659A4 (en) * | 2009-09-08 | 2013-03-27 | Merck Sharp & Dohme | HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
EP2493302A4 (en) * | 2009-10-30 | 2013-04-24 | Merck Sharp & Dohme | Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators |
EP2493303A1 (en) * | 2009-10-30 | 2012-09-05 | Merck Sharp & Dohme Corp. | 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS |
EP2493302A1 (en) * | 2009-10-30 | 2012-09-05 | Merck Sharp & Dohme Corp. | Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators |
EP2493303A4 (en) * | 2009-10-30 | 2013-06-26 | Merck Sharp & Dohme | 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS |
WO2018191283A1 (en) * | 2017-04-11 | 2018-10-18 | Oric Pharmaceuticals, Inc. | Glucocorticoid receptor modulators |
CN112771046A (en) * | 2018-07-20 | 2021-05-07 | 格吕伦塔尔有限公司 | Other substituted triazoloquinoxaline derivatives |
CN112771046B (en) * | 2018-07-20 | 2023-09-19 | 格吕伦塔尔有限公司 | Other substituted triazoloquinoxaline derivatives |
US11981677B2 (en) | 2018-07-20 | 2024-05-14 | Grünenthal GmbH | Further substituted triazolo quinoxaline derivatives |
WO2020076999A1 (en) * | 2018-10-10 | 2020-04-16 | Oric Pharmaceuticals, Inc. | Glucocorticoid receptor modulators |
WO2020152193A1 (en) | 2019-01-22 | 2020-07-30 | Akribes Biomedical Gmbh | Selective glucocorticoid receptor modifiers for treating impaired skin wound healing |
Also Published As
Publication number | Publication date |
---|---|
ATE464296T1 (en) | 2010-04-15 |
EP1599201A2 (en) | 2005-11-30 |
AU2004216182A1 (en) | 2004-09-10 |
EP1599201B1 (en) | 2010-04-14 |
DE602004026558D1 (en) | 2010-05-27 |
WO2004075840A3 (en) | 2005-02-03 |
WO2004075840A9 (en) | 2005-08-04 |
CA2516684A1 (en) | 2004-09-10 |
EP1599201A4 (en) | 2007-01-24 |
JP2006518752A (en) | 2006-08-17 |
US7411073B2 (en) | 2008-08-12 |
JP4648303B2 (en) | 2011-03-09 |
US20060074120A1 (en) | 2006-04-06 |
AU2004216182B2 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004075840A2 (en) | Selective non-steroidal glucocorticoid receptor modulators | |
AU2004207482B2 (en) | 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators | |
AU2003270783C1 (en) | Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators | |
AU2003221706B2 (en) | 1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators | |
WO2021259224A1 (en) | Triazine benzoate compound and application thereof | |
AU2009217493B2 (en) | Hexahydrocyclopentyl[f]indazole carboxamides and derivatives thereof as selective glucocorticoid receptor modulators | |
AU2004232301B2 (en) | Selective spirocyclic glucocorticoid receptor modulators | |
US20120214847A1 (en) | 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | |
CA2716136A1 (en) | Hexahydrocyclopentyl[f]indazole sulfonamides and derivatives thereof as selective glucocorticoid receptor modulators | |
US20120172397A1 (en) | HEXAHYDROCYCLOPENTA[f]INDAZOLE 5-YL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | |
WO2010138421A1 (en) | HEXAHYDROCYCLOPENTYL[f]INDAZOLE REVERSED AMIDES AND DERIVATIVES AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS | |
JP2008540657A5 (en) | ||
US20120095055A1 (en) | HEXAHYDROCYCLOPENTYL[f]INDAZOLE 5-HYDROXYMETHYL ETHANOLS AND DERIVATIVES THEREOF AS SELECTIVE GLUCOCORTICOID RECEPTOR MODULATORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004216182 Country of ref document: AU |
|
COP | Corrected version of pamphlet |
Free format text: PAGE 1, DESCRIPTION, ADDED |
|
ENP | Entry into the national phase |
Ref document number: 2006074120 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10544899 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2004216182 Country of ref document: AU Date of ref document: 20040220 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004216182 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2516684 Country of ref document: CA Ref document number: 2004713398 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006503780 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004713398 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10544899 Country of ref document: US |